izalontamab brengitecan (BL-B01D1) - BMS, Systimmune
Izalontamab Brengitecan (iza-bren) in Patients with Advanced Cervical Cancer (CC) or Endometrial Cancer (EC) Progressed on Platinum-Based Chemotherapy (PBC): Results from Two Phase II Studies (ESMO Asia 2026) - Oct 1, 2026 - Abstract #251P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available 
Clinical • Metastases • P2 data • Cervical Cancer • Endometrial Cancer • Oncology • Solid Tumor
https://cslide.ctimeetingtech.com/asia2026/attendee/confcal/print/presentation/1763
 
Rujiao Liu; Xiaohua Wu; Jian Zhang; Xiumin Li; Yuping Sun; Naifu Liu; Yi Huang; Hanmei Lou; Dapeng Li; Tao Wu; Jundong Li; Wei-Hu Wang; Lingying Wu; Li Wang; Kaijia Tu; Sa Xiao; Hai Zhu; Yi Zhu
 
Oct 1, 2026
 
Prev Next